Pasithea Therapeutics Business Summary

Pasithea Therapeutics Corp. (KTTA) is a clinical-stage biotechnology company that generates value through the research and development of its proprietary drug pipeline, primarily focusing on RASopathies and central nervous system (CNS) disorders. The company operates through two primary segments: Therapeutics, centered on its lead candidate PAS-004—a next-generation macrocyclic MEK inhibitor—and a secondary Clinics segment that provides administrative support for specialized depression treatments. As of February 2026, Pasithea remains pre-revenue, recently securing a $60 million public offering in December 2025 to fund operations through the first half of 2028. Its competitive landscape includes established players such as AstraZeneca (Koselugo) and SpringWorks Therapeutics (mirdametinib); however, Pasithea positions PAS-004 as a potential best-in-class therapy, leveraging its unique macrocyclic structure to offer superior safety, tolerability, and pharmacokinetic profiles compared to existing acyclic MEK inhibitors. The company’s leadership is anchored by Executive Chairman and Co-Founder Prof. Lawrence Steinman, a renowned Stanford University professor who previously co-founded Neurocrine Biosciences and Atreca. Dr. Tiago Reis Marques serves as Chief Executive Officer, bringing a background as a senior clinical fellow at Imperial College London and a practicing psychiatrist at Maudsley Hospital. The executive team is further strengthened by CFO Daniel Schneiderman, formerly of First Wave BioPharma, and Chief Development Officer Dr. Graeme Currie. Pasithea’s strategic direction is supported by a high-pedigree board and a notable institutional investor base that includes Vivo Capital, Janus Henderson Investors, Adage Capital Partners, and Squadron Capital Management, all of whom led the company's most recent major financing round.